Advertisement
Screener

Protara Therapeutics, Inc. (TARA) Foreign Currency Transaction Gain (Loss), Unrealized

1.8 / 5 stars · 19/54 Roast Me

Protara Therapeutics, Inc. Foreign Currency Transaction Gain (Loss), Unrealized

Protara Therapeutics, Inc. (TARA) reported Foreign Currency Transaction Gain (Loss), Unrealized of $127.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-13.

Discontinued › Cash Flow › Operating Activities

us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2019-03-13

  • Protara Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2016-12-31 was $0.00.
  • Protara Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2016-09-30 was $2.00K.
  • Protara Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2016-06-30 was -$53.00K.
  • Protara Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2016-03-31 was $178.00K.
  • Protara Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2016 was $127.00K.
  • Protara Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2015 was -$537.00K.
Period endForeign Currency Transaction Gain (Loss), Unrealized 3 monthForeign Currency Transaction Gain (Loss), Unrealized 6 monthForeign Currency Transaction Gain (Loss), Unrealized 9 monthForeign Currency Transaction Gain (Loss), Unrealized 12 month
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13
$2.00K
derived: sum of 2 quarters · filed 2019-03-13
-$51.00K
derived: sum of 3 quarters · filed 2019-03-13
$127.00K
10-K · filed 2019-03-13
2016-09-30$2.00K
10-Q · filed 2017-11-07
-$51.00K
derived: sum of 2 quarters · filed 2017-11-07
$127.00K
10-Q · filed 2017-11-07
$16.00K
derived: sum of 4 quarters · filed 2018-03-14
2016-06-30-$53.00K
10-Q · filed 2017-08-07
$125.00K
10-Q · filed 2017-08-07
$14.00K
derived: sum of 3 quarters · filed 2018-03-14
-$300.00K
derived: sum of 4 quarters · filed 2018-03-14
2016-03-31$178.00K
10-Q · filed 2017-05-10
$67.00K
derived: sum of 2 quarters · filed 2018-03-14
-$247.00K
derived: sum of 3 quarters · filed 2018-03-14
-$359.00K
derived: sum of 4 quarters · filed 2018-03-14
2015-12-31-$111.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14
-$425.00K
derived: sum of 2 quarters · filed 2018-03-14
-$537.00K
derived: sum of 3 quarters · filed 2018-03-14
-$537.00K
10-K · filed 2018-03-14
2015-09-30-$314.00K
10-Q · filed 2016-11-07
-$426.00K
derived: sum of 2 quarters · filed 2016-11-07
-$426.00K
10-Q · filed 2016-11-07
2015-06-30-$112.00K
10-Q · filed 2016-08-08
-$112.00K
10-Q · filed 2016-08-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Alector, Inc. (ALEC)United States$0.213B-1.90
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90